المؤلفون: A. Duffy, S. Patten, S. Goodday, A. Weir, N. Heffer, A. Cipriani

المصدر: International Journal of Bipolar Disorders, Vol 5, Iss 1, Pp 1-6 (2017)

مصطلحات موضوعية: Lithium, Mania, Child and adolescent, Systematic review, Bipolar disorder, Acute treatment, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurophysiology and neuropsychology, QP351-495

الوصف: Abstract Background Epidemiological, clinical, and high-risk studies have provided evidence that the peak period for onset of diagnosable episodes of mania and hypomania starts in mid-to-late adolescence. Moreover, clinically significant manic symptoms may occur even earlier, especially in children at familial risk. Lithium is the gold standard treatment for acute mania in adults, yet to our knowledge, there is no published systematic review assessing lithium treatment of mania in children or adolescents. This is a major gap in knowledge needed to inform clinical practice. Aim As a working group within the ISBD Task Force on Lithium Treatment ( http://www.isbd.org/active-task-forcesTest ), our aim is to complete a systematic review of the efficacy, tolerability, and acceptability of lithium compared with placebo and other active drugs in treating mania in children and adolescents diagnosed with bipolar disorder. Methods We will include double- or single-blind randomized controlled trials in patients aged less than 18 years. No restrictions will be made by study publication date or language. Several electronic databases will be searched along with secondary sources such as bibliographies and trial registry websites for published and unpublished studies. Response rates to lithium compared with placebo or other active drugs will be the primary efficacy outcome. Primary tolerability and acceptability outcomes will be rates of serious adverse events and dropouts, respectively. Secondary outcomes will include rates of remission, severity of manic symptoms at different time points, and incidence of specific adverse events. Discussion Findings from this systematic review are critically needed to inform clinical practice. We should not generalize findings from adult studies, as children and adolescents are undergoing accelerated physiological and brain development. Therefore, efficacy, tolerability, and acceptability of lithium treatment of acute mania in children compared to adults may be very different. This systematic review has been registered in PROSPERO (CRD42017055675).

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s40345-017-0092-6Test; https://doaj.org/toc/2194-7511Test

الوصول الحر: https://doaj.org/article/7b67691b93b748bdb72a5f164791e1f8Test

المؤلفون: Sarah M. Goodday, Scott B. Patten, Anne Duffy, N. Heffer, Andrea Cipriani, Arielle Weir

المصدر: International Journal of Bipolar Disorders, Vol 5, Iss 1, Pp 1-6 (2017)
International Journal of Bipolar Disorders

مصطلحات موضوعية: Pediatrics, medicine.medical_specialty, Lithium (medication), Bipolar disorder, Short Communication, Lithium, Placebo, law.invention, lcsh:RC321-571, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, medicine, Adverse effect, Psychiatry, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Biological Psychiatry, lcsh:QP351-495, medicine.disease, 030227 psychiatry, Psychiatry and Mental health, Mania, Hypomania, lcsh:Neurophysiology and neuropsychology, Tolerability, Systematic review, Child and adolescent, medicine.symptom, Psychology, Acute treatment, 030217 neurology & neurosurgery, medicine.drug

الوصف: Background Epidemiological, clinical, and high-risk studies have provided evidence that the peak period for onset of diagnosable episodes of mania and hypomania starts in mid to late adolescence. Moreover, clinically significant manic symptoms may occur even earlier, especially in children at familial risk. Lithium is the gold standard treatment for acute mania in adults, yet to our knowledge, there is no published systematic review assessing lithium treatment of mania in children or adolescents. This is a major gap in knowledge needed to inform clinical practice. Aim As a working group within the ISBD Task Force on Lithium Treatment (http://www.isbd.org/active-task-forcesTest) our aim is to complete a systematic review of the efficacy, tolerability, and acceptability of lithium compared to placebo and other active drugs in treating mania in children and adolescents diagnosed with bipolar disorder. Methods We will include double or single-blind randomized controlled trials in patients aged less than 18 years. No restrictions will be made by study publication date or language. Several electronic databases will be searched along with secondary sources such as bibliographies and trial registry websites for published and unpublished studies. Response rates to lithium compared to placebo or other active drugs will be the primary efficacy outcome. Primary tolerability and acceptability outcomes will be rates of serious adverse events and dropouts, respectively. Secondary outcomes will include rates of remission, severity of manic symptoms at different time points, and incidence of specific adverse events. Discussion Findings from this systematic review are critically needed to inform clinical practice. We should not generalize findings from adult studies, as children and adolescents are undergoing accelerated physiological and brain development. Therefore, efficacy, tolerability, and acceptability of lithium treatment of acute mania in children compared to adults may be very different. This systematic review has been registered in PROSPERO (CRD42017055675).

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac738d3b734a8c58179d689fa1a521ffTest
http://link.springer.com/article/10.1186/s40345-017-0092-6Test